News and Events
Stem cell–derived natural killer cells engineered to attack solid tumors
Cancer-killing natural killer cells could pave the way to off-the-shelf immunotherapy for solid tumors.
Read MoreCCR researchers receive a range of HHS awards
Three CCR researchers received prestigious awards from the Department of Health and Human Services. They are being recognized for their excellence, dedication and achievements in their respective research fields.
Read MoreCCR researchers elected to the Association of American Physicians
Elaine S. Jaffe, M.D., NIH Distinguished Investigator in the Laboratory of Pathology, and Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch, were elected as 2024 members of the Association of American Physicians. The organization seeks to inspire physician-led research across all fields of science and medicine to improve patient health care and the health of Americans.
Read MoreCelebrating CCR Careers: Mark Gilbert, M.D.
Mark Gilbert, M.D., has been a neuro-oncologist for nearly four decades, working to find better treatments for people with rare brain and spine tumors. After nearly a decade at CCR as Chief of the Neuro-Oncology Branch, he is announcing his retirement.
Read MoreNIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
In a proof-of-concept study published on April 18, 2024, in Nature Cancer, CCR researchers have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug. The team, led by Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, suggests that such single-cell RNA sequencing data could one day be used to help doctors more precisely match cancer patients with drugs that will be effective in treating their cancer.
Read MoreJung-Min Lee appointed Senior Investigator at CCR
The CCR community congratulates Jung-Min Lee, M.D., who has been appointed as a Senior Investigator in the Women’s Malignancies Branch. Lee’s research focuses on developing targeted therapies for ovarian carcinoma. Her studies have identified key proteins of DNA damage response pathways as therapeutic targets, opening up possibilities for novel therapies for this disease. Her research also emphasizes the collection of patient samples to better understand treatment response and tumor biology.
Read MoreClinical trial researching medication therapy for IDH2-mutated nasal cavity or skull base tumors
A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching targeted medication therapy for patients with IDH2-mutated tumors in the nasal cavity or skull base area.
Read MoreCellular processing reverses molecule’s effect on anticancer immunity
Immune cells convert an immunosuppressive lipid into an anticancer immunity enhancer.
Read MoreLeah Cook appointed Senior Investigator at CCR
The CCR community welcomes Leah M. Cook, Ph.D., who has been appointed as a Senior Investigator in the Cancer Innovation Laboratory. She is a cancer biologist with a focus on metastasis and the metastasis microenvironment. The goal of her research program is to identify mechanisms associated with bone metastatic prostate cancer and specifically, the underpinnings of the immune-tumor bone environment that contribute to metastatic disease.
Read MoreClinical trial researching post-treatment care for prostate cancer
A trial led by Deborah E. Citrin, M.D., Senior Investigator in the Radiation Oncology Branch, is studying the use of a device for improving urinary issues after prostate cancer treatment.
Read MoreFirst Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma
On February 16, 2024, the Food and Drug Administration approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes (TILs), for some people with advanced melanoma. TIL therapy was pioneered in the 1980s by Steven A. Rosenberg, M.D., Chief of the Surgery Branch, and the final approval of this treatment has taken years of clinical trial research and ongoing partnerships among multiple institutions.
Read More